Nuformix PLC Change of Auditor (0956D)

TIDMNFX

RNS Number : 0956D

Nuformix PLC

01 March 2022

1 March 2022

Nuformix plc

("Nuformix" or the "Company")

Change of Auditor

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Jeffreys Henry LLP ("Jeffreys Henry") as auditor to the Company. The appointment of Jeffreys Henry will be subject to approval by shareholders at the next Annual General Meeting of the Company.

The appointment of Jeffreys Henry follows the resignation of Haysmacintyre LLP who has confirmed to the Company that there are no circumstances connected with its resignation which it considers should be brought to the attention of the members or creditors of the Company. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.

Enquiries:

 
 Nuformix plc 
 Dr Alastair Riddell, Executive Chairman    Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  [phone] 
 John Howes (Corporate Broking)             [phone] 
 IFC Advisory Limited 
 Tim Metcalfe                               [phone] 
  Zach Cohen                                 [e-mail] 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAXAPAALAEFA

(END) Dow Jones Newswires

March 01, 2022 02:01 ET (07:01 GMT)